Evidence map›Paper›PMID 30630429›Full record

ArticleBMC infectious diseases2019

Cost of three models of care for drug-resistant tuberculosis patients in Nigeria.

Florence O Bada, Evaezi Okpokoro, Nick Blok, Emmanuel Meribole, Saswata Dutt, Patrick Dakum, Alash'le Abimiku, Alice Zwerling, Sandra V Kik

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Cost of TB prevention and treatment in the Philippines in 2017.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Florence O BadaInternational Research Center of Excellence, Institute of Human Virology Nigeria, 252 Herbert Macaulay Way, Central Business District, Abuja, Nigeria. fbada@ihvnigeria.org.ORCID http://orcid.org/0000-0002-0212-3907
Evaezi OkpokoroInternational Research Center of Excellence, Institute of Human Virology Nigeria, 252 Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Nick BlokKNCV Tuberculosis Foundation, The Hague, The Netherlands.
Emmanuel MeriboleDepartment of Health, Planning, Research and Statistics, Federal Ministry of Health, Abuja, Nigeria.
Saswata DuttInternational Research Center of Excellence, Institute of Human Virology Nigeria, 252 Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Patrick DakumInternational Research Center of Excellence, Institute of Human Virology Nigeria, 252 Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Alash'le AbimikuInternational Research Center of Excellence, Institute of Human Virology Nigeria, 252 Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Alice ZwerlingKNCV Tuberculosis Foundation, The Hague, The Netherlands.
Sandra V KikKNCV Tuberculosis Foundation, The Hague, The Netherlands.
Institute of Human Virology · NGTuBerculosis Vaccine Initiative · NLUniversity of Maryland, Baltimore · USFederal Ministry of Health · NGUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is required to guide the scale up of DR-TB care. We aimed to estimate and compare the costs of different DR-TB treatment and care models in Nigeria.

methodsWe estimated the costs associated with three models of DR-TB treatment and care: Model (A) patients are hospitalized throughout the 8-month intensive phase, Model (B) patients are partially hospitalized during the intensive phase and Model (C) is entirely ambulatory. Costs of treatment, in-patient and outpatient care and diagnostic and monitoring tests were collected using a standardized data collection sheet from six sites through an ingredient's approach and cost models were based on the Nigerian National Tuberculosis, Leprosy and Buruli Ulcer Guideline - Sixth Edition (2014) and Guideline for programmatic and clinical management of drug-resistant tuberculosis in Nigeria (2015).

resultsAssuming adherence to the Nigerian DR-TB guidelines, the per patient cost of Model A was $18,528 USD, Model B $15,159 USD and Model C $9425 USD. Major drivers of cost included hospitalization (Models A and B) and costs of out-patient consultations and supervision (Model C).

conclusionUtilizing a decentralized ambulatory model, is a more economically viable approach for the expansion of DR-TB care in Nigeria, given that patient beds for DR-TB treatment and care are limited and costs of hospitalized treatment are considerably more expensive than ambulatory models. Scale-up of less expensive ambulatory care models should be carefully considered in particular, when treatment efficacy is demonstrated to be similar across the different models to allow for patients not requiring hospitalization to be cared for in the least expensive way.

Indexed as

AdultAmbulatory CareAntitubercular AgentsCosts and Cost AnalysisDrug CostsFemaleHospital CostsHospitalizationHumansMaleNigeriaTreatment OutcomeTuberculosis, Multidrug-ResistantAntitubercular AgentsCostDecentralized ambulatory careDrug-resistant tuberculosisHospitalization

Identifiers

PMID30630429
PMCPMC6327521
OpenAlexW2912833927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.